Cancer Therapy Redefined
We are Genegenesis. Committed to addressing the problem of tumor heterogeneity and overcoming therapy resistance in melanoma.
Melanoma
The doctors say that you have 18 months to five years left to live, what do you do?
This is the question that Stage IV melanoma cancer patients face every day. Once the tumor has spread to organs, it has metastasized and is considered a stage IV melanoma.
Most Common Cancer
Did You Know?
324,635 people were diagnosed with melanoma in 2020 worldwide
97,610 adults in the USA are diagnosed with invasive melanoma of the skin.
Melanoma is 20 times more common in White people than in Black people.
The average age of diagnosis is 65
Current Treatments are Ineffective
1
Misdiagnosis
2
Inappropriate Treatment Decisions
3
Treatment Resistance
Who We Are
We are young researchers that have come together for one single purpose: To solve the problem of tumor heterogeneity and identify therapeutic solutions that would address therapeutic resistance in melanoma
Research
Our research focuses on the initiatives specific to tumor heterogeneity in melanoma
Our Initiatives
1
Precision Targeting of TFAP-2 Using CRISPR Containing LIpid Nanoparticles
2
Study DEGs in Primary and Metastatic Melanoma
3
Correlation of shape of 3D Culture Masses with the expression of Metastasis-inducing genes
4
Simple Bioimaging Study To Investigate Levels of Biomarkers That Lead to Tumor Progression and Metastasis in Melanoma
5
Research Study to Understand How Heterogeneity Contributes to Resistance
Get Involved
For questions or enquiries, simply fill out a contact form Or Send us an Email.
